Researchers reviewed the current evidence surrounding sodium-glucose co-transporter 2 (SGLT-2) inhibitors, traditionally used as anti-hyperglycemic drugs, as they have emerged as a significant treatment for heart failure (HF), proving effective across varying degrees of heart function (left ventricular ejection fraction or LVEF). Their therapeutic potential was first indicated in a 2013 trial for type 2 diabetes mellitus (T2DM). Subsequent studies reaffirmed the effectiveness of SGLT-2 inhibitors in decreasing HF hospitalizations and cardiovascular death, suggesting their benefits aren’t solely based on their anti-hyperglycemic properties. Researchers noted the importance of properly integrating SGLT-2 inhibitors into HF treatment plans to enhance patient outcomes and reduce healthcare costs.

Reference: Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023 Mar 13;5(2):82-90. doi: 10.36628/ijhf.2022.0030. PMID: 37180562; PMCID: PMC10172076.